-
Recent Posts
- Timeless Good Advice? (Action for Happiness)
- The Diversionary Value of Music Playlists for Patients With Dementia in Accident and Emergency Settings (Nurses.co.uk / BBC News)
- More on the Possible Role of Neuroinflammation in Frontotemporal Dementia (Bazian / Brain)
- COVID-19 Infection: Coronavirus in the UK (DHSC / PHE / BBC News / SCIE / NHS England)
- Interventions to Improve Resilience in People Living With Dementia (Frontiers in Medicine)
Archives
- April 2020
- March 2020
- February 2020
- January 2020
- December 2019
- November 2019
- October 2019
- September 2019
- August 2019
- July 2019
- June 2019
- May 2019
- April 2019
- March 2019
- February 2019
- January 2019
- December 2018
- November 2018
- October 2018
- September 2018
- August 2018
- July 2018
- June 2018
- May 2018
- April 2018
- March 2018
- February 2018
- January 2018
- December 2017
- November 2017
- October 2017
- September 2017
- August 2017
- July 2017
- June 2017
- May 2017
- April 2017
- March 2017
- February 2017
- January 2017
- December 2016
- November 2016
- October 2016
- September 2016
- August 2016
- July 2016
- June 2016
- May 2016
- April 2016
- March 2016
- February 2016
- January 2016
- December 2015
- November 2015
- October 2015
- September 2015
- August 2015
- July 2015
- June 2015
- May 2015
- April 2015
- March 2015
- February 2015
- January 2015
- December 2014
- November 2014
- October 2014
- September 2014
- August 2014
- July 2014
- June 2014
- May 2014
- April 2014
- March 2014
- February 2014
- January 2014
- December 2013
- November 2013
- October 2013
- September 2013
- August 2013
- July 2013
- June 2013
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
Categories
- Antipsychotics
- Assistive Technology
- Charitable Bodies
- Commissioning
- Delirium
- Depression
- Enhancing the Healing Environment
- Falls
- Falls Prevention
- Guidelines
- Hip Fractures
- Housing
- Hypertension
- In the News
- Integrated Care
- International
- Local Interest
- Mental Health
- Models of Dementia Care
- National
- ADASS
- All-Party Parliamentary Group (APPG) on Dementia
- BSI
- CQC: Care Quality Commission
- Department of Health
- Department of Health and Social Care (DHSC)
- Health Education England (HEE)
- Housing LIN
- MAGDR
- Mental Health Foundation
- Mental Health Network (NHS Confederation)
- MHP Health Mandate
- National Audit Office
- National Voices
- NEoLCIN
- NEoLCP
- NHS
- NHS Alliance
- NHS Confederation
- NHS Employers
- NHS England
- NHS Evidence
- NHS Improvement
- NICE Guidelines
- NIHR
- NIHRSDO
- Northern Ireland
- Patients Association
- Public Health England
- RCN
- Royal College of Physicians
- Royal College of Psychiatrists
- SCIE
- Scotland
- UK
- UK NSC
- Wales
- Non-Pharmacological Treatments
- Nutrition
- Pain
- Parkinson's Disease
- Patient Care Pathway
- Person-Centred Care
- Personalisation
- Pharmacological Treatments
- Proposed for Next Newsletter
- Quick Insights
- Standards
- Statistics
- Stroke
- Systematic Reviews
- Telecare
- Telehealth
- Universal Interest
Google Translate (100+ Languages)
Tag Archives: Solanezumab Trials
Alzheimer’s Disease: Solanezumab Drug Trial Flops (BBC News / Alzheimer’s and Dementia)
Summary The phase 3 EXPEDITION3 trial has been abandoned, as Solanezumab failed to slow cognitive decline in tests on around 2,000 patients with Alzheimer’s Disease. Several other amyloid-clearance drugs are going through trials apparently. Full Text Link Reference Walsh, F. … Continue reading
Posted in BBC News, For Researchers (mostly), In the News, International, Pharmacological Treatments, Quick Insights, Universal Interest
Tagged Alzheimer’s and Dementia (Journal), Alzheimer’s Disease Clinical Trials, Amyloid, Amyloid Beta, Amyloid Beta Protein, Amyloid Proteins, Amyloid-β (Aβ), Amyloid-β (Aβ) Accumulation, Avid Radiopharmaceuticals (Philadelphia), BBC Health News, Big Pharma, Clearance of Amyloid Beta Protein, Drug Trials, Drug Trials Failure Rate, Eli Lilly, Eli Lilly and Company (Indianapolis), EXPEDITION Studies, Intervention Trials, β-amyloid, LZAM, LZAN, Mild Alzheimer’s Disease, Misfolded Proteins, Neurofibrillary Tangles, Neuronal Loss, Progression of Mild Cognitive Impairment to Dementia, Progression to Alzheimer's Disease, Reasons for Termination of Trials, Solanezumab (Eli Lilly), Solanezumab EXPEDITION Trials, Solanezumab for Mild-to-Moderate Alzheimer’s Disease, Solanezumab Trials, Solanezumab: Humanised Monoclonal Antibody, United States, USA
Leave a comment
Solanezumab Trials Results for Mild-to-Moderate Alzheimer’s Disease (New England Journal of Medicine)
Summary Solanezumab is a monoclonal antibody which binds soluble amyloid preferentially and had shown some promise of promoting better clearance of amyloid-beta from the brain in pre-clinical studies. Two placebo controlled trials (EXPEDITION 1 and EXPEDITION 2) of 1012 and … Continue reading
Posted in For Doctors (mostly), For Researchers (mostly), International, Pharmacological Treatments
Tagged Alzheimer's Disease and Memory Disorders Center: Baylor College of Medicine (Houston), Alzheimer's Disease Assessment Scale (ADAS-Cog11), Alzheimer's Disease Cooperative Study Steering Committee, Alzheimer's Disease Cooperative Study-Activities of Daily Living scale (ADCS-ADL), Alzheimer's Disease Cooperative Study: University of California at San Diego, Amyloid, Amyloid Beta, Amyloid Beta Protein, Amyloid Proteins, Amyloid-β (Aβ), Amyloid-β (Aβ) Accumulation, Baylor College of Medicine, Beta-Amyloid, Beta-Amyloid Plaques, Center for Human Experimental Therapeutics: University of Rochester Medical Center, Centre Hospitalier Universitaire Toulouse, Clinical Trials Number: NCT00904683, Clinical Trials Number: NCT00905372, Department of Neuropathology: University of Tokyo, Eli Lilly, Gerontopole: Unité Mixte de Recherche, Gliosis, Indiana Alzheimer Disease Center: Indiana University, Indiana University, β-amyloid, Neurofibrillary Tangles, Neuronal Loss, New England Journal of Medicine, Solanezumab for Mild-to-Moderate Alzheimer’s Disease, Solanezumab Study Group, Solanezumab Trials, Solanezumab: Humanised Monoclonal Antibody, University of California at San Diego, University of Pennsylvania, University of Rochester Medical Center
Leave a comment
